Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Mahipal on Treatment of Newly Diagnosed mCRC

March 22nd 2019

Amit Mahipal, MBBS, professor of medicine, Mayo Clinic, discusses the treatment of patients with newly diagnosed metastatic colorectal cancer.

GI Oncologist Sheds Light on Present and Future of mCRC Treatment

March 21st 2019

Amit Mahipal, MBBS, discusses navigating the complex treatment paradigm of metastatic colorectal cancer and sheds light on how recent advances are impacting the outlook of those affected by the disease.

Encorafenib/Binimetinib-based Triplet Added to NCCN Guidelines for BRAF+ CRC

March 18th 2019

The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E–mutant metastatic colorectal cancer, after failure of 1 or 2 lines of therapy for metastatic disease.

Dr. Strickler on Therapies for Rare Variants of Relapsed/Refractory CRC

March 13th 2019

John Strickler, MD, assistant professor of medicine at Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses therapies for rare variants of relapsed/refractory colorectal cancer.

Expert Highlights Evidence-Based Decision-Making in mCRC

March 11th 2019

Michael S. Lee, MD, sheds light on the treatment options available in the metastatic colorectal cancer space and highlights strategies poised to improve patient outcomes.

Dr. Jiang on the Future of Immunotherapy in Microsatellite Stable Colorectal Cancer

March 9th 2019

Yixing Jiang, BM, PhD, associate professor of medicine, director, Gastrointestinal Medical Oncology Marlene Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, discusses the future of immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Strickler Stresses Continued Focus on Molecular Subtypes in mCRC

March 9th 2019

John Strickler, MD, highlights important data in the metastatic colorectal cancer space and challenges that remain for oncologists working in the field.

Dr. Marshall on Personalized Chemotherapy in CRC

March 5th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses personalized chemotherapy in the treatment of patients with colorectal cancer.

Management of Metastatic CRC Rooted in Molecular Subsets

March 5th 2019

John L. Marshall, MD, discusses the current and future scope of metastatic colorectal cancer.

EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications

March 5th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.

Immunotherapy, Chemo Approaches Continue to Build in CRC and Pancreatic Cancer

March 5th 2019

Douglas A. Nelson, MD, discusses key advances made in the treatment of patients with colorectal cancer and pancreatic cancer, and sheds light on remaining challenges in these paradigms.

Younger Patients With CRC Misdiagnosed, Diagnosed at Later Stages

February 28th 2019

Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer.

Dr. Overman Discusses ReDOS Study in mCRC

February 26th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the ReDOS study in patients with metastatic colorectal cancer.

Molecular Testing Needed to Inform CRC Treatment Decisions

February 25th 2019

Michael Overman, MD, highlights data from pivotal trials presented at the 2019 Gastrointestinal Cancers Symposium and discusses where research efforts should be focused to improve the treatment of patients with colorectal cancer.

Dr. Eng on Recognizing Tumor Sidedness in mCRC

February 23rd 2019

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses recognizing tumor sidedness in the treatment of patients with metastatic colorectal cancer.

Eng Highlights Important Treatment Considerations in mCRC

February 22nd 2019

Cathy Eng, MD, FACP, discusses the current treatment options available for patients with metastatic colorectal cancer and highlights recent data in the space.

Dr. Lee on the Benefit of Cytoreductive Surgery in Metastatic Colorectal Cancer

February 21st 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the benefit of cytoreductive surgery in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Nelson on Novel Combination Therapies in Colorectal Cancer

February 19th 2019

Douglas A. Nelson, MD, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel combination therapies in colorectal cancer (CRC).

Dr. Mizrahi on Bevacizumab as a Chemoprotectant in CRC

February 15th 2019

Jonathan Mizrahi, MD, hematology/oncology fellow, The University of Texas MD Anderson Cancer Center, discusses bevacizumab (Avastin) as a chemoprotectant in colorectal cancer (CRC).

Dr. Kasi on Role of Immunotherapy in mCRC

February 14th 2019

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with metastatic colorectal cancer.